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1. Introduction
1.1. Regulation of mineralization in bone and soft tissue
The first stages of cell mediated tissue bio-mineralization involve the activation of various
signaling pathways, such as those activated by growth factors and hormones like BMPs, TGFs,
PTH, Leptin, Vitamin D and many others.
One major signaling pathway responsible for bio-mineralization is the Wnt-pathway. Wnt-
mediated transduction occurs via both β-catenin dependent and independent signaling. In β-
catenin dependent signaling, extracellular Wnt ligands bind to the LRP5-Frizzled (Frz)
complex, subsequently inhibiting an intracellular cluster of molecules comprised of axin,
glycogen synthase kinase 3 (GSK3), and the adenomatosis polyposis coli (APC) protein. This
complex then inhibits the cytosolic degradation of β-catenin, which accumulates and subse‐
quently enters the nucleus to heterodimerize with two important transcription factors, LEF
and TCF, conferring the Wnt-effect on gene transcription. Via the β-catenin independent
signaling pathway, a similar complex forms between Wnt, Frz, and Ror2, which stimulate the
synthesis of secondary messengers [1, 2].
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Another important pathway is the one mediated via Hedgehog. The Hedgehog (HH) ligand
precursor is subjected to a series of modifications before reaching an active, multimeric form.
This process releases the transcription factor Smoothened (SMO), which in turn activates the
Gli2/3 complex, which goes on to promote gene expression of Gli1, while repressing the
transcriptional repressor Gli3 [3].
A third pathway is the NELL-1 signaling pathway. NELL-1 is a secretory osteoinductive
protein, binding to the cell surface receptors Integrinβ1&3. A multitude of intracellular
signaling pathways are activated due to NELL-1 stimulation. These include MAPK, Hedgehog,
and β-catenin dependent Wnt-signaling. Despite the fact that these pathways are still unde‐
fined, NELL-1 activation enhances Runx2 transcription and phosphorylation, and develop‐
ment of an osteogenic phenotype [4].
The last stage of bio-mineralization encompasses the precipitation of hydroxyapatite crystals,
which spontaneously results in supersaturated or metastable salt solutions. Whether bio-
mineralization will take place, is determined by the genetic programming of precursor cells
into a mineralization-competent state (as in physiological bone formation=osteogenesis) or to
pathological mineralization (i.e. ectopic mineralization or calcification) [5]. Hence, all tissues
which are not meant to minerealize, should be actively “protected” or inhibited from precip‐
itation of mineral. Fetuin-A is a circulating protein produced by the liver, directly inhibiting
ectopic mineralization. Monomeric fetuin-A protein binds small clusters of both calcium and
phosphate. This interaction results in the formation of prenucleation cluster-laden fetuin-A
mono-and polymers, calciprotein monomers, and considerably larger soluble aggregates of
protein and mineral calciprotein particles of colloid (soluble) nature [6, 7].
In this manner, fetuin-A serves as a mineral carrier protein and a systemic inhibitor of
pathological mineralization, i.e. mineralization not brought about by bone residing osteoblasts,
but by fibroblast like cells demonstrating mineralizing phenotypic characteristics.
1.2. Untoward calcification of soft tissues; some model systems
Vascular calcification inevitably afflicts the aging and dysmetabolic population. Modern
concepts state that this process has emerged as a highly regulated form of bio-mineralization
organized by collagenous and elastin extracellular matrices. Paracrine osteogenic signals,
mediated by potent morphogens of the bone morphogenetic protein (BMPs) and wingless-
type integration site family member (Wnt) superfamilies, are also active in the programming
of arterial osteoprogenitor cells during vascular and heart valve calcification. Inflammatory
cytokines, as well as reactive oxygen species, and oxylipids (which are more active within the
clinical settings of atherosclerosis, diabetes, and uremia) elicit the ectopic vascular activation
of osteogenic morphogens. Specific inhibitors (e.g. MGP, CV2, COMP2, Noggin, Gremlin,
Chordin, and Folliastatin) of bone BMP-Wnt signaling have been identified, contributing to
the modulation of osteogenic mineralization during development and disease. These inhibi‐
tory pathways and their regulators afford therapeutic strategies to prevent and treat valve and
vascular sclerosis [1, 3].
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In this context, the expression of vascular BMP-2 and BMP-4 (mostly elaborated by endothelial
cells) are actively enhancing [Smad-DNA]-binding, thus trans-activating a cascade of factors
like Msx2, Runx2, NFATc1 and Osterix (SP7), deemed necessary in the mineralizing process
[1, 3]. The downstream pro-osteogenic signaling cascades initiated through heterodimer BMP
receptors is held in check by a panoply of extracellular BMP binding proteins and intracellular
transcriptional inhibitors (I-Smads, i.e. Smad6 and Smad7) [1, 3].
Calcific aortic valve stenosis (CAVS) is an increasing health problem affecting aging societies.
The discovery of osteoblast-like and osteoclast-like cells in the heart have forced a paradigm
shift where CAVS is considered to be actively regulated. It has also been shown that valvular
fibrosis, as well as calcification, plays an important role in restraining cusp movement.
Furthermore, CAVS should probably be regarded as a fibro-calcific ailment [8, 9].
It has been speculated what type of precursor cells are being able to turn into osteoblast-like
cells in aortic valves, giving rise to human calcific aortic valve stenosis. Activated myofibro‐
blasts are likely to come from either quiescent valvular interstitial cells (VICs) or from a
subpopulation of endothelial cells that undergo an “endothelial to mesenchymal transforma‐
tion” (EMT) [1, 8, 10]. Lastly, it has been asserted that circulating osteoprogenitor cells (positive
for OPN and ALP) may enter the active side of the valve from the circulation [9]. Hence, it
should be noted that a lack of “bone-homing” of osteoblast-precursors, as seen in the elderly
population, may lead to the development of CAVS. It is also noteworthy that monocytes may
enter the valve tissue, transform into osteoclast-like cells and/or inflammatory Th-cells, and
thus affect the above mentioned osteoprogenitor cells to start a mineralization process due to
their response to TNFα and interleukins [1, 8, 9].
Blood vessels are the first to form in the developing embryo and build extensive networks
supplying all cells and organs with nutrients and oxygen. An ageing blood vessel often
becomes abnormal in structure and function, thus contributing to a plethora of age-related
diseases like ischemic heart&brain-disease, neurodegeneration, and/or cancer. The first
regulators to be linked to the aging process were the Forkhead box “O” (FOXO) transcription
factors and sirtuin (Sirt) deacetylases [9, 11]. They are now emerging as key regulators of the
vascular development and disease. The integration of FOXO-and Sirt-family members into the
aspect of vessel maintenance, offers new perspectives on mechanisms of aging, which is the
most important risk factor for diseases of vascular system [9, 10].
The FOXO transcription factors control a plethora of cellular responses, encompassing
apoptosis, DNA-repair, metabolism, as well as ROS detoxification and cell proliferation. On
stimulation of PI3K/AKT-signaling by growth factors, AKT phosphorylates FOXOs on
conserved residues with ensuing cytoplasmic sequestration and inactivation [1, 10]. Of specific
interest for the precipitation of atherosclerotic plaques is FOXO3A, however, FOXO1 and
FOXA3 should also be mentioned, since they has been shown that they hetero-dimerize with
the transcription factor SXR, known to bind vitamin K2 [12-14].
The Sirts (especially Sirt1) are involved in the modulation of key genes involved in regulating
lifespan and health span, including AMP-activated protein kinase (AMPK), mammalian target
of rapamycin (mTOR), and insulin-like growth factor 1 (IGF-1), and their roles modulating
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cardiovascular health status [15, 16]. It is to be noted that the FOXO class of transcription factors
affect the levels of sirtuins (including Sirt1), thus enabling the body’s cell-and tissue arma‐
mentarium to respond to the energy state (NAD+/NADH-ratio) in a proper manner to preserve
organ function and longevity [10, 15]. In this context, the FOXOs and sirtuins are both
instrumental for the heart and vasculature to avoid the numerous detrimental alterations
during ageing.
Finally, the present report focusses on altered gene expression leading to proper or disturbed
calcification of bone and soft tissues, as a result of perturbed transcription or posttranscrip‐
tional control. Particularly, certain transcription factors (TFs) and microRNAs (miRNAs) will
be described [17, 18], which are members of so-called regulatory loops [19].
Interestingly, several groups or clusters of miRNAs, targeting several hundred mRNA species
encoding TFs, as well as tissue specific or non-specific genes, have been shown to impact
conditions like cardiac hypertrophy and cardiac fibrosis [17, 18].
1.3. MicroRNAs in atherosclerogenesis
The dysregulation of cholesterol homeostasis is one of the underlying causes of atherosclerosis.
One regulatory factor in cholesterol metabolism includes the sterol regulatory element-binding
protein (SREBP) family, which regulates the expression of a plethora of cholesterogenic genes
[20]. The microRNA species 33b and 33a, respectively, have been shown to target the ATP-
binding cassette A1 cholesterol transporter [21], which mediates intracellular cholesterol efflux
from cells to form HDL that is protective against atherosclerosis [22, 23]. Upon injection of
antisense miR-33 into western diet-fed mice, serum HDL levels were significantly elevated,
and treatment of LDL-receptor deficient animals with anti-miR-33, resulted in augmented
levels A1 in both liver and macrophages, with a net increase in blood HDL-levels along with
reduced plaque size and inflammation-related gene expression [23].
However, other microRNA species, such as the miR-145/143 cluster, miR-133, and miR-221,
exert a more direct role in atherogenesis. The miR-145/miR-143 cluster is enriched in visceral
and vascular smooth muscle cells (VSMC) from early embryonic days and throughout
adulthood [24-26]. Genomic deletion of this cluster yielded a mild vascular phenotype with
no cardiac abnormalities, however, smooth muscle cells were smaller and exhibited an increase
in rough endoplasmic reticulum (RER) and a decrease in actin stress fibers, resulting in thinner
tunica media [26]. The failure to detect a consistent increase in VSMC proliferation or apoptosis
indicates the miRNA cluster is involved in the ability of VSMC to differentiate in response to
contractile demands [25].
Krupple-like factor-5, first identified as a transcription factor inducing the gene expression of
smooth muscle myosin heavy chain, is involved in smooth muscle proliferation by stimulating
cyclin D1 expression [27, 28]. MiR-133 is known to be enriched in the heart and skeletal muscle,
but one report asserts that it is also expressed in smooth muscle cells [29]. Over-expression of
miR-133 in the carotid artery has been shown to halt VSMC proliferation and prevent neoin‐
timial hyperplasia [17]. Interestingly, the level of miR-133 in this tissue exhibits a strong inverse
correlation with its targets, one of which is the transcription factor SP1, and it may be asserted
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that SP1 inhibition leads to a deactivation of Krupple-like factor-5, which in turn prevents
down-regulation of Myh11 (myosin heavy chain gene family), and hence VSMC phenotype
switching and proliferation [17].
In contrast to miR-145 and miR-133, miR-221, but not the co-clustered miR-222, positively
regulates smooth muscle proliferation [30]. It is believed to be induced by platelet-derived
growth factor (PDGF), which is known to stimulate VSMC switching and proliferation during
angiogenesis and neo-intimal formation [31]. In gain-and-loss-of function experiments, it was
demonstrated that miR-221 was required for mediating the effects of PDGF on the suppression
of the cell-cycle inhibitors p27Kip1&2, and c-kit [30, 31]. The effects of miR-221 are reinforced
by the concurrent up-regulation of miR-21 in neointimal lesions, and miR-21 was shown to
inhibit PTEN, which acts as a dual-specificity protein phosphatase, dephosphorylating
tyrosine-, serine- and threonine-phosphorylated proteins [32-34], antagonizing the PI3K-AKT/
PKB signaling pathway [35]. In this manner, miR-21 inversely modulates apoptotic VSMC
death and reduces neo-intimal thickness. Consequently, neo-intimal formation is brought
about by a combinatorial effect of changes in the expression of several miRs and their targets,
with ensuing regulation of VSMC differentiation, proliferation, and survival.
However, the scope of the present book chapter, is to focus on microRNA species being
involved in the process of matrix mineralization, whether or not they are intrinsic miRs
residing within osteoblasts or smooth vascular cells or “imported” miRs via exosomes shedded
by immune cells (like macrophages and Th-cells) invading the vasculature due to inflamma‐
tory processes. One may assert that microRNA species down-regulated in mineralizing
osteoblasts should be up-regulated in healthy, non-calcifying soft tissues like blood vessels
and heart valves. However, this is a simplification of the issue, since the acquired osteoblastic
or mineralizing phenotype is secured by a balanced impact of microRNAs targeting osteogenic
markers (or modulators) like BMP-2, SMADs, Runx2, Osterix (SP7), Dkk-1, and RANKL and
others, a loss of calcification inhibitors like MGP and Fetuin-A, and finally a loss of smooth
muscle cell markers like α-actin and certain MHC-class of antigens, as shown by Goettsch and
co-workers [18]. This major compilation of published literature indicates that several micro‐
RNAs well known to be down-regulated in osteoblasts (like the miR-species 23a, 24, 27a, 29a,
34c, 133a, 135a, 149, 204, and 328) [36-39] are not necessarily down-regulated in “mineralizing”
or “calcifying” vascular cells.
Interestingly, it has been shown that Th17-cells produce exosomes containing high levels of
microRNAs (like miR-16, -24, -27a ,-27b, -125b, and -586) known to be low in developing and
mature osteoblasts [36, 37], while also carrying high levels of, amongst many; miR-21, -22, -221,
-222, and -520 (data not shown). According to Goettsch et al. [18], miR-21 is up-regulated in
atherosclerotic arteries, while all the other mentioned miRNAs are down-regulated in arteries,
plaques or bicuspid aortic valves. It is therefore necessary to define a cluster of minimal and
sufficient microRNAs, which may represent a signature for soft tissue calcification. Hitherto,
we do not see that such a cluster has been suggested, nor validated.
It is therefore of major interest to seek help from bioinformatics software to define regulatory
loops, consisting of microRNAs, transcription factors and marker genes, known to be sensitive
and prone to alterations in precursor cells, but resilient to changes in defined phenotypes. It
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is therefore exciting to learn that miR-133, already known to affect SP1 [40] seems to be players
in regulatory loops, consisting of a selection of microRNA species and transcription factors,
where miR-22, -27, -29, -133, -149, and -328, are connected to FOS, ETS1, SP1, SP3, RUNX1,
FOSB, and EGR2, in a reciprocal feed-forward and feed-back stabilizing network.
2. The histopathology of vascular calcification
Vascular calcium deposition can be usefully organized into four histoanatomic variants. As
outlined, each type of vascular calcification is associated with a characteristic spectrum of
vascular disease processes. Moreover, in the setting of the calcified atherosclerotic plaque and
senile calcific aortic sclerosis, the initial dystrophic calcification process evolves during
vascular injury and remodeling into endochondral, non-endochondral, or mixed ossification
mechanisms.
2.1. Atherosclerotic calcification
Atherosclerotic calcification is a dystrophic calcification characterized by cellular necrosis,
inflammation, and the presence of lipoprotein and phospholipid complexes [41, 42].  The
lipid complexes,  originating from cellular membranes,  thrombo-fibrinoid complexes,  and
circulating lipoproteins precipitate calcium in association with atherosclerotic plaques. The
ensuing endothelial  cell  dysfunction provides a thrombogenic surface coated with fibrin
and  phospholipids,  which  drive  additional  lipid  deposition.  Oxidized  lipid  products
provide  several  signals  that  recruit  and  activate  macrophages  and  T-cells  [43].  The
calcification  appears  first  in  the  lipid  core  of  the  fibro-calcific  plaques,  juxtaposed  to
inflammatory  cell  infiltrates  and  necrotic  areas.  Eventually,  calcified  cartilage  formation
follows the degenerative tissue calcification via a vascular remodeling process, leading to
the deposition of endochondral bone [43].
2.2. Calcification of cardiac valves
Cardiac valve calcification occurs following mechanical stress and inflammation, leading to
dystrophic mineralization and non-endochondral ossification. Degenerative lipid accumula‐
tion, fatty expansion of the valvular fibrosa, and interstitial calcium deposition are rapidly
followed by the invasion of macrophages and T-cells [44, 45]. Hence, valve calcification of the
young and elderly, is initiated via overlapping mechanisms, but distinct from calcification
observed within atherosclerotic plaques [46-49]. However, during progression of the calcifi‐
cation process, histological and molecular analyses indicate that a secondary phase of active,
osteogenic mineral deposition perpetuates the vascular calcium accumulation, but via non-
endochondral processes [50, 51].
2.3. Medial artery calcification
Calcification of the medial artery is a non-endochondral ossification process of the arterial
tunica media, occurring frequently in patients suffering diabetes and end-stage renal disease
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[52]. The mineralization pattern resembles intra-membranous calvarial bone formation and
odontogenesis [53], driven by the BMP-2/Msx1&2-dependent signaling pathway in the
absence of any cartilaginous precursor [54-56]. Many hypotheses of the major molecular
determinants of medial calcification vs atherosclerotic calcification with cartilage metaplasia,
have been launched, however, these determinants remain elusive. Two model systems may
render some clues, though: the characteristics of vascular calcification responses of the
(LDLR-/-) and (apoE-/-) mice [55-57]. Both animal model systems develop atheroma; however,
LDLR-/- mice calcify valves and tunica media via a non-endochondral osteogenic process, while
apoE-/- mice calcify vessels via cartilage metaplasia.
It has been shown that a myofibroblast cell population, activated by diet-induced diabetes, is
diverted to the osteoblast lineage by Msx2-dependent transcriptional programming [54-56]. It
was therefore asserted that this migratory myofibroblast population, which responds to
vascular smooth muscle cell (VSMC) osteopontin (OPN) production [56, 58, 59], contributes
to vascular remodeling and the medial calcification of diabetes. Interestingly, both hypergly‐
cemia [56, 58] and hyperphosphatemia [60] induce OPN expression, which per se is a consistent
and predicted feature of medial calcification [61-63]. Furthermore, the absence of the osteo‐
protegerin (OPG) gene expression in mutant mice also results in medial calcification with
ensuing vascular T-cell infiltration [64]. Noteworthy is the observation that blood levels of
OPG are increased in diabetic humans [65] and diabetic (LDLR-/-) mice [55], which may indicate
a state of resistance to OPG, namely inhibition of RANK-L signaling. It has been shown that
the OPG/RANK-L secretion ratio is enhanced in carotid plaques compared to femoral plaques,
which explains why carotid plaques contain less calcium and number of macrophages and T-
cells [43].
2.4. Vascular calciphylaxis (soft tissue calcification)
Vascular calciphylaxis occurs when the calcium phosphate solubility threshold is exceeded
[66]. When the serum calcium-phosphate product exceeds this threshold, widespread soft
tissue deposition of amorphous calcium phosphate will occur. To prevent this happening, an
array of mineralization inhibitors have evolved, encompassing fetuin-A, tissue pyrophosphate
generating systems, as well as tissue OPN production [67].
Fetuin-A, which is an abundant serum glycoprotein, has been shown to limit organ and soft
tissue calcification, including vascular calcium deposition [67]. Pyrophosphate inhibits
nucleation and epitaxial calcification and also up-regulates the expression of OPN [68, 69]. The
generation of tissue pyrophosphate is obtained via ectonucleotide pyrophosphatases/phos‐
phodiesterases (ENPPs). ENPP1 (or PC-1) is instrumental in limiting calcification in “soft
tissues”, like blood vessels, skeletal muscle fibers, ligaments and tendons [68, 69].
2.5. Vascular calcification and cartilage metaplasia
In vertebrates, bone formation occurs via both endochondral and non-endochondral mecha‐
nisms [53]. In endochondral ossification, avascular cartilage is subjected to vascular invasion,
cartilage calcification, remodeling by osteoclasts, and eventually deposition of bone by
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osteoblastic cells. Endochondral bone formation and neovascularization depend heavily on
the expression of Runx2, acting in concert with Sox9 [53, 70]. The array of molecular players
in endochondral ossification is also associated with the progression of untoward, degenerative
atherosclerotic calcification [71], as shown in models of heritable vascular calcification [72,
73]; matrix Gla protein (MGP) knockout mice and apoE knockout mice, which both develop
arterial cartilage metaplasia.
In this context, MGP functions as a noggin-like inhibitor of vascular BMP-2 mediated signaling
[74]. Hence, in the absence of MGP, enhanced BMP-2 signaling may promote vascular cartilage
metaplasia. Loss of the intracellular BMP-R2 signaling inhibitor Smad6 also provokes arterial
cartilage metaplasia and medial endochondral bone formation [75]. Noteworthy is that BMP-2
signaling can drive both chondrogenic and osteogenic differentiation of multipotent mesen‐
chymal precursor cells [76]. However, it is important to emphasize that there is a finely tuned
balance between sustained Msx2 expression, which will promote osteogenic differentiation at
the expense of adipocyte and chondrocyte development [54, 63] and “intermittent” Msx2
expression. The former will secure functional bone remodeling, while the latter is meant to
prohibit mineralization of soft tissues [43]. Unfortunately, this balance may be tilted in both
directions, resulting in less mineralized bone tissue and untoward calcification of soft tissues.
2.6. The modulatory effect of vitamin K2
Vitamin K1 and the VCOR activation cycle is apparently of great importance for the status
of  bone  health  through the  influence  of  bone  derived carboxylated osteocalcin  (OC)  on
several other organ systems, like pancreas (insulin secretion), adipose tissue (adiponectin
secretion) and testis (testosterone production), which all form reciprocally interacting organs
in a homeostatic organ cross-talk system [77-80]. However, since vitamin K2 (MK-7 and/or
MK-4)  has  been shown to  be  a  ligand for  the  steroid and xenobiotic  receptor  SXR also
designated pregnane X receptor PXR, orphan nuclear receptor PAR1, and NR1/2 [81], the
knowledge of which genes are transcribed with the aid of MK-7 or MK-4 in different organ
systems or cells [12-14, 82, 83], is vital to understand how vitamin K2 status affects organ
homeostasis  in  general,  and  especially  bone  health  and  the  regulation  of  detrimental
mineralization of soft tissues in particular [1, 8-10, 84].
Apart from the up-regulation of mRNAs for OC, BMP-2, and RANK-L, and alleviation of
TNFα-mediated suppression of pro-bone SMAD expression in osteoblasts [13, 14], it has been
shown that MK-7/4 in bone acts as a general transcriptional regulator of extracellular matrix-
related genes that are involved in the collagen assembly (indicated by gene ontology analyses).
Hence, MK-7/4 synergizes with calcitriol (active vitamin D=1,25(OH)2D3) in maintaining bone
growth and homeostasis throughout life. However, it seems that MK-7/4 deserve a closer
scrutiny, since there are a plethora of additional modulatory hormone-like effects exerted by
this “vitamin”, as envisaged by its modulatory effect on gene expression in osteoblastic cells.
Some interesting features are summarized in the table underneath:
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Gene Biological effect related to biomineralization processes
CSNK1A (casein kinase 1)
(see Gene Card)
Modulates Wnt and hedgehog (HH) signaling pathways, which play a major role in the
differentiation of stem cells to osteoblasts, and contributes to the features of mineralizing
osteoblasts
FETUB, fetuin B
(see Gene Card)
Enables super-saturation of free Ca-Pi molecules, thus prohibiting precipitation of
calcium-hydroxyapatite crystals in soft tissues
MAPK9 (MAP Kinase 9)
(see Gene Card)
When activated, promotes β-catenin (CTNNB1) degradation and inhibits
the canonical Wnt signaling pathway
SMAD2
(SMAD family member 2)
(see Gene Card)
SMAD2 is involved as a transcription factor contributing to the activity of SMAD2/
SMAD3:SMAD4 heterotrimer and down-regulation of TGF-β receptor signaling.
Involved in the regulation of osteoblastogenesis and acquisition of mineralizing
properties of cells in general
JUN (c-JUN, JUNB, JUND)
(see Gene Card)
Part of the dimeric AP1 complex. JUN associates with FOS, thereby affecting
differentiation of osteoblasts, osteoclasts, as well as immune cells (e.g. T-cells)
RYK (Receptor-Like
Tyrosin Kinase)
(see Gene Card)
May be a co-receptor along with FZD8 of Wnt proteins,
such as WNT1, WNT3, WNT3A and WNT5A
(of which WNT3A&5A are important for osteoblastogenesis and mineralization)
CRSP3 (Mediator complex
subunit 23)
(see Gene Card)
The protein encoded by this gene is a subunit of the
CRSP complex, necessary for
efficient activation by SP1
Table 1. Genes affected by Vitamin K2 (MK-7 or MK-4), as described by “Gene Card” on the Web. The genes tabulated
are involved in biomineralization processes as described by Slatter and co-workers [85].
In short, vitamin K2, without any doubt, heavily affects the phenotypic characteristics of
osteoblastic cells, i.e. both differentiation of stem cells to mature osteoblasts, as well as their
mineralizing capacity. Furthermore, it seems that vitamin K2 is involved in the steady state
level of SP1, the transcription factor, shown to be implicated in reciprocal regulatory loops
with several microRNA species known to be discriminators of osteoblast differentiation and
function [1, 3, 36-38]. Hence, it may be postulated that vitamin K2 may serve as an important
modulator of the process of bio-mineralization, stabilizing cell phenotypes within a narrower
span of features. In other words, vitamin K2 may optimize mineral deposition in bone, while
blocking untoward mineralization in soft tissues.
3. Putative problems, and future directions
The interaction between hormonal, metabolic, inflammatory, and mechanical stressor mole‐
cules, as well as passive mineralization inhibitors determines the ultimate “phenotype” of
osteoblasts mediating mineralization in bone, as well as vascular progenitors regulating the
deposition of calcium in soft tissues. However, several issues have yet to be resolved concern‐
ing the regulation of vascular calcification. Firstly, a detailed comprehension of the origins of
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the chondro-and osteo-progenitors is still elusive [43]. Secondly, the relative contribution of
trans-differentiating VSMCs and migratory myofibroblasts to vascular calcification responses
is not fully understood [43]. Additionally, a “homing response” induced by a vascular injury
will probably recruit circulating marrow skeletal progenitors [86] and contribute to damage
progression, including the development of ectopic vascular bone marrow in association with
vascular osteogenesis [43]. And finally, a better (i.e. minimal, but necessary and/or exhaustive)
set cell surface markers of the mesenchymal cell lineage seem to be required.
Furthermore, the impact of T-cells and macrophages in vascular calcification is not fully
understood, but may explain the reciprocal relationships between bone turnover and vascular
calcification. One interesting phenomenon is the shedding of microRNA-containing exosomes
from these immune cells [87]. Hence, future efforts in identifying which of these miRNA
species and other factors, which may “alter” the phenotype of the fibroblast like cells in vessels
and heart valves, are welcomed.
In a clinical setting, once vascular osteogenic tissue has acquired the ability to form mature
bone, there is a possibility that anabolic bone-building hormones intended to treat osteoporosis
may also augment mineral deposition in soft tissues via coupled matrix turnover processes. It
should also be taken into consideration that diseases, like end stage renal disease (ESRD),
hyperglycemia, hypertension, hypercholesterolemia, hyperphosphatemia, PTH-resistance,
and iatrogenic calcitriol excess may all contribute to the vascular calcium load [88-90].
Hence,  it  seems  that  the  reciprocally  regulated  calcification  of  various  body  organs/
tissues leaves little “space” for non-overlapping phenomena: calcification in bone with no
soft tissue mineralization, and decalcification of soft tissues without losing bone mass. To
solve the problematic issue of these tied and reciprocal phenomena, on may resort to apply
the fine-tuning ability of  bio-molecular “players” like vitamin K2.  This vitamin,  with its
hormonal actions through the transcription factor SXR, seems to enable the body to control
both bone mineralization and strength [91-93] and counteract soft tissue calcification in an
optimal fashion [81, 94].
4. Materials and methods
In general, the description of materials and methods used is depicted in Figure 1. The results
presented in this chapter are based on the following:
Materials: Human mesenchymal stem cells (hMSCs), human fibroblasts/HUVECs were either
from in-house stock strains, or obtained from commercial sources. Human MSCs were
differentiated to osteoblasts and heart valvular interstitial cells (VICs) according to standard
procedures [95], while the fibroblasts/HUVECs were used directly on demand. The cells were
exposed to appropriate media and differentiation protocols described elsewhere [96]. Fur‐
thermore, bovine calf bone chips were obtained fresh from the slaughterhouse and incubated
with or without PBMCs differentiated to osteoclasts, according to standard procedures [97-99].
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Methods (incubations, manipulations and analyses): The data presented herein mainly
emanate from manipulation of differentiated cells (transfected with vectors expressing various
transcription factors, i.e. SP1, ETS1, and RUNX1) in control and mineralizing media (see above)
with siRNAs, pre-miRNAs and/or antago-miRNAs (corresponding to miR-149 and miR-328)
in the presence or absence of either cytokines (TNFα, IL-1, IL-6, and IL-17A) or vitamin K2
(MK-7). End point analyses of results obtained were performed using mRNA isolation
techniques (Quiagen), Q-PCR analyses of pertinent gene transcripts according to the literature
[100-102], ELISA-based quantification of secreted cell marker growth factors/cytokines and
others (e.g. osteocalcin, IL-10, TGFβ, OPG, and RANK-L). Finally, mineralization surface was
measured using the Alizarin red S dye on cells in monolayers [103].
Bioinformatics: Interactions between microRNA-species, transcription factors (TFs) and cell
phenotype “specific” marker genes were emulated using the Mir@nt@n algorithm [19]. On the
charts, genes and microRNAs are visualized like this: TFs in red boxes; miRNAs in orange
rectangles.
Statistics: Mean values were considered significantly different from controls when p < 0.05
(non-parametric testing, n=9) (refs). Differences compared to controls are marked with a star *.
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Figure 1. Illustration of interconnected experiments contained within a differentiation scheme of stem cells towards
osteoblasts, manipulation of cellular phenotypes in the absence and presence of inflammatory cells or their cytokines,
as well as analyses of parameters pertaining to matrix deposition and its calcification.
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5. Results
5.1. Bioinformatics analyses using the Mir@nt@n algorithm
Figure 2, which is based on available osteoblast transcriptome data, featuring modulated
transcription factor (TF) mRNAs and microRNAs (miRs), shows that ETS1, SP1, and RUNX1
(encircled in green) are involved in feed-forward/feed-back regulatory loops with several miRs
included within the Stein [38] and Gordeladze [37] “miR-signatures” for osteoblastic cells. The
emulation was performed with the highest possible stringency. Other TFs within the same
network system are FOS, FOSB, SP3, and EGR2.
 
Transcription 
factors 
 
MicroRNA species «connected» 
  
SP1 Let-7f, 18b, 24, 27a, 27b, 29a, 29c, 31, 96, 135b, 141, 149, 182, 
200a, 377, 522, 597 
ETS1 19a, 34a, 125a-5p, 133b, 135b, 148b, 206, 222, 328, 377, 492, 522 
FOSB 23a, 23b, 27a, 27b, 152, 182, 200a, 204, 220c, 224, 637, 638 
RUNX1 17, 20a, 20b, 23a, 27a, 27b, 30a, 91, 93, 106a, 141, 494 
JUNB Let-7a,c,d,f, 15a, 93, 326, 494, 597 
EGR2 20b, 23a, 25, 106a, 137 
SPI1 34a, 155, 326, 663 
FOS 29a, 29c, 149, 597 
SP3 133b, 135b, 182, 191 
JUN 9, 200b, 522, 637 
STAT1 20a, 20b 
SOX9 206 
  
Figure 2. Tabulation of transcription factors (TFs) targeted by various microRNA species (either predicted by the
Mir@nt@n algorithm or directly shown in experiments with reporter constructs). TFs and microRNAs focused on in
this chapter are highlighted in yellow and red (the Gordeladze osteoblast-“signature”) or green (the Stein-“signature”),
respectively.
Figure 3 shows the result of a Mir@nt@n emulation with low stringency, indicating that SP1,
ETS1, FOSB, and RUNX1, are the TFs putatively binding the largest number of microRNA
species. It should be emphasized that the “Stein-signature” of miRs (highlighted in green) are
involved with more TFs than the “Gordeladze-signature” (highlighted in red), indicating that
the former is a better marker and/or predictor of the osteoblast phenotype.
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Figure 3. High stringency emulation of feed-forward and feed-back (“reciprocal”) regulatory loops encompassing tran‐
scription factors and microRNA species using osteoblast transcriptomes and microRNA species known to be involved
in the differentiation and/or function of mineralizing osteoblastic cells [19].
Figure 4 shows the network of interacting TFs and miRs of the “Gordeladze-signature”
including histone deacetylaces (HDACs) emphasizing the important feed forward/feed-back
loops involving SP1 and ETS1 with the microRNA species 149 and 328. Many of the “Gorde‐
ladze-signature miRs are interacting with sirtuins (e.g. SIRT1, one HDAC subspecies), which
indicates that the regulatory TF-miR system is influenced by the osteoblast’s energy status,
since it is known that the NAD+/NADH-ratio is influencing the activity of HDACs [10].
Figure 5a&b shows Q-PCR-data on transcription factor, marker gene and microRNA levels,
as well as mineralizing surface (%) in osteoblasts exposed to cytokines (cfr. Methods) trans‐
fected with vectors containing SP1, ETS1 or RUNX1, or TF+cytokines (average of all three TFs
from separate experiments). In essence, the two panels indicate that the cytokine mix is
detrimental to the osteoblasts, and that over-expression of the transcription factors or antago-
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miRs counteract the negative impact of the cytokines on the osteoblast phenotype. Sections of
Alizarin red S colored osteoblasts are depicted underneath the tables.
Figure 6 a&b indicates the same type of analyses/data as Figure 5. Here, Q-PCR-data and per
cent mineralizing surface are presented. DKK1, which is an inhibitor of osteoblastogenesis is,
inversely regulated within the various treatment groups, compared to the other markers.
However, the data set grossly indicates that cytokine exposure “deprives” the osteoblasts of
their phenotype markers, while overexpression of either transcription factor (SP1, ETS1 or
RUNX1) in the presence of all cytokines “reinstates” the osteoblast phenotype characteristics.
Figure 7 shows one Mir@nt@n-emulation of regulatory network lattices consisting of osteoblast
related transcription factors and microRNA species. The insert shows that the vitamin K2
receptor SXR (also known as NR1I2) associates with miR-760, which is tied to JUNB in a
reciprocal looping system, connecting vitamin K2 to a network resembling the one featured in
Fig. 2. However, vitamin K2 apparently needs miR-597 to connect to this looping system. The
significance of miR-597 is discussed in Section 6.3.
Figure 8 depicts the effect of the vitamin K2 analogue MK-7 (menaquinone-7) on the secretory
function of osteoblasts embedded in bovine bone slices exposed to either, MK-7 (10 ng/ml),
SXR-siRNA or pre-miR-760. Clearly, MK-7 exposure of the bone chips for 7 days enhances the
secretory profile (osteocalcin, IL-10, TGFβ, OPG and RANKL) measured with ELISA-kits.
Furthermore, concomitant incubations with either SXR-siRNA or pre-miR-760 obliterate the
effect of MK-7.
Figure 9 shows the impact of the transcription factors FoxA3 and FoxO1 on Runx2 expression
in osteoblastic cells (left). Clearly, siRNA directed against either transcription factor obliterates
Figure 4. High stringency emulation of microRNA species interacting with transcription factors (TFs), functional mark‐
er genes and the complete published “Gordeladze mini-signature” of microRNAs in osteoblasts, including histone de‐
acetylases (HDACs and Sirtuins=Sirts). Insert: Resiprocal regulatory loops involving the miR-24,-149, and-328, and the
TFs SP1, FOS, and ETS1.
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Figure 5. Tabulation of osteoblast-related parameters (transcription factors=TFs, microRNAs and mineralizing surface)
measured in osteoblasts differentiated from hMSCs, in the presence or absence of MK-7, cytokines or both. All values
are given as a percentage of controls (=100%). All results are means of separate experiments with the TFs indicated.
Figures marked by stars (*) indicate p-values < 0.01.
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Figure 6. Tabulation of osteoblast-related parameters (transcription factors=TFs, microRNAs and mineralizing surface)
measured in osteoblasts (fig. a) or fibroblasts/HUVECs/VICs (fig. b) isolated from human tissues or differentiated from
hMSCs, in the presence or absence of cytokines and transcription factors (SP1, ETS1 or RUNX1) expressing constructs.
All values are given as a percentage of controls (=100%). All results are means of separate experiments with the TFs
indicated. Figures marked by stars (*) indicate p-values < 0.01.
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the stimulatory effect of MK-7 on Runx2 mRNA. It is well known that insulin and various
growth factors modulate the activity of both FoxA and FoxO species via the PI3-
Kinase/Akt/PKB signaling pathway, indicating that vitamin K2 is able to modulate hormonal
or growth factor mediated impact on osteoblasts and possibly also other cell phenotypes.
Figure 10a&b depicts how osteoblasts (a) or fibroblasts/HUVECs/VICs (b) transfected with
empty vectors, respond to the exposure of MK-7, a cytokine mixture (see text-Fig 8) or
MK-7+cytokines in terms of transcription of genes and microRNAs, modulating mineral
deposition in their surrounding matrix.
Figure 11 summarizes the effect (“correction”) of transcription factors (TFs), microRNA species
and vitamin K2 on the phenotypic characteristics of osteoblasts, fibroblasts, HUVECs and
VICs. By manipulating different cell phenotypes with TFs and miRs engaged in reciprocal
regulatory loops, in the presence of vitamin K2, it may be possible to stabilize and/or correct
cell phenotypes to restrict mineralization of extracellular matrix to organs where mineral
deposition is wanted (bone) and inhibit calcification of soft tissues like blood vessels and heart
valves. Pay special attention to the reciprocal regulation of Runx2/SP7/BGP vs Matrix GLA
protein (MGP) in osteoblasts and fibroblasts/ HUVECs/VICs.
Figure 7. Mir@nt@n emulation [19] of osteoblast transcription factors=TFs and microRNAs, including miR-760, which
was shown to putatively couple to NR1I2=SXR with the highest binding characteristics (the Sanger microRNA Data‐
base), known to be a receptor for vitamin K2 (i.e. MK-7 and/or the metabolite MK-4.
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6. Discussion
6.1. The importance of regulatory loops for the control of cellular phenotype
Feed-forward and feed-back regulatory loops consisting of transcription factors (TFs) and
microRNAs are parts of an epigenetically “stabilizing” machinery [104]. Three categories of
signals are proposed to operate in establishing a resilient, heritable epigenetic state. An
extracellular signal designated the ‘‘epigenator’’, conveyed from the environment, triggers the
start of the epigenetic pathway. The ‘‘epigenetic initiator’’ receives the signal from the
‘‘epigenator’’ and determines the precise chromatin location and/or DNA environment for
establishing the epigenetic pathway. The ‘‘epigenetic maintainer’’ sustains the chromatin
environment in both the initial and succeeding generations. Persistence of the chromatin milieu
may require cooperation between the initiator and the maintainer. Hence, microRNAs and
TFs, once they have attained an interactive “steady state”, function as “maintainers” of a given
cell phenotype with defined characteristics.
Figure 8. Secretory profile (osteocalcin, IL-10, TGFβ, OPG, and RANK-L) of mature osteoblasts within freshly isolated
bovine bone chips for 7 days (days 8-14) after being pre-conditioned for 7 days (day 1-7) with either MK-7 (10 ng/ml),
siRNA against SXR, or pre-miR-760.
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From a literature search (PubMed) on “SP1 transcription factor and osteoblasts”, SP1 is
somehow interfering with the effect of Runx2, SP7 (Osx), FIAT (inhibitor of ATF4), ETS-like
TFs, MZF1 (myeloid zinc finger), JunB, and also directly affecting the transcription of marker
genes like Col1α1, Col5α1, Col5α3, Col11α2, Fibromodulin, Osteocalcin, MGP (matrix-gla
protein), RANKL, Pit phosphate transporter, Integrin β5, and TGFβ-R1. Furthermore, a similar
search on “FosB and osteoblasts” revealed that FosB is interfering with the effect of BMPs and
TGFs on the expression of downstream signaling molecules like Smads, TCF/LEF, as well as
c-myc, and fra-1, but also directly modulating the transcription of IL-11 (which suppresses
DIKK1 & DIKK2, thus enhancing Wnt-signaling), stimulating Pref-mediated dedifferentiation
of adipocytes, relaying stretch-mediated osteoblast differentiation, counteracting the negative
effect of Notch1 (a decrease in the expression of Col1α1, Osteocalcin, and ALP) by obliterating
its negative effect on the Wnt/β-catenin pathway. Finally, the recent literature describes the
positioning of ETS1 in the differentiation of osteoblasts in this way: Leptin is a strong inducer
of osteoblast differentiation working through Stat3 (ref), and it was shown that ETS1, along
with Stat1, Stat3, and VDR were induced by Calcitriol (1,25(OH)2D3) in UMR-106 osteoblast
like cells, and that ETS1 is essential for connective tissue factor (CTGF/CCN2) induction by
TGF-β1 in osteoblasts, synergizing with Smad3.
A B C D 
FoxA1  FoxA2  FoxA3  FoxO1  FoxO3A  FoxO4 
PI3-Kinase 
Insulin & Growth Factors 
Akt/PKB 
Figure 9. Left: Expression of Runx2 (Q-PCR) in osteoblasts differentiated from hMSCs in the absence (controls) or pres‐
ence of MK-7 (10 ng/ml), MK-7+either FoxO1 -or FoxOA3-siRNAs (featuring two separate experiments). Right: Sche‐
matic representation of the impact of MK-7 on the signaling systems driven by insulin and growth factors (TGFs/
BMPs) on the transcription of genes via PI3-kinase and the Akt/PKB-system, as described in the literature [108].
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Figure 10. Tabulation of recently recognized “discriminating” (for comparison, see Figures 6a&b) osteoblast-related
parameters (transcription factors=TFs, microRNAs and mineralizing surface) measured in osteoblasts (fig. a) or fibro‐
blasts/HUVECs/VICs (fig. b) isolated from human tissues or differentiated from hMSCs, in the presence or absence of
cytokines and transcription factors (SP1, ETS1 or RUNX2) expressing constructs. All values are given as a percentage
of controls (=100%). All results are means of separate experiments with the TFs indicated. Figures marked by stars (*)
indicate p-values < 0.01.
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Furthermore, BMP2 stimulation of pre-osteoblasts is mediated through ETS1, which trans-
activates Osteopontin, Runx2, PTHrP, and Col1α1 genes. The most compelling evidence for
the importance of ETS1 (together with SP1 and SP7=Osx) on conferring the osteoblast pheno‐
type of differentiating cells, is that the Runx2 P1 promoter in mesenchymal cells is co-
stimulated at purine-rich DNA sequences (Y-repeats). It has also been shown that mechano-
stimulation of MSCs enhances ETS1, Runx2, and ALP transcription and translation in a
sequential manner, and that RNF11, also deemed necessary for osteoblastogenesis, in fact, is
regulated by ETS1. Finally, the AJ18 gene, which is as a novel KRAB/C82/H(2) gene implicated
in the differentiation of osteogenic cells, displays several response elements for proteins like
ETS1 and SP1, as well as Runx2, Smads and NFκB.
It may be asserted that the larger number of microRNAs involved in the modulation of the
activity of a certain cell’s TFs, the more stable the cellular phenotype will become, and the more
finely tuned its functions will be. Hence, it may be postulated that the alteration of the steady
state levels of players contained within reciprocal regulatory loops in osteoblasts, may also
determine whether the cells in other organs than bone may acquire mineralizing characteristics
or not. Our results clearly state that this is the case, since it was possible to fortify the miner‐
alizing phenotype of osteoblasts, and weaken the mineralizing properties of fibroblasts,
HUVECs and VICs by manipulating the levels of SP1, ETS1, and RUNX1, or the levels of
osteoblast-“specific” signature-microRNAs, like miR-149 and miR-328 [36, 37]. Suppression of
miR-149 enhances the mRNA level of target proteins associated with the differentiation of
osteoblasts (Runx2, APC2, RNF11, and SP1). At the same time, a reduction in miR-149 will
Osteoblast Fibroblast/ 
HUVEC/VIC 
Inflammatory cytokines 
(and exosomes containing 
proteins & microRNAs?) 
Phenotype alterations: 
«loss of mineralization 
capacity» 
Phenotype alterations: 
«gain of mineralization 
capacity» 
 
«Corrections»/ 
normalization of 
cell phenotype 
obtained by 
manipulating levels 
of transcription 
factors (like SP1, 
ETS1 and 
RUNX1) and 
microRNAs (like 
149, 328, 27, 
29 133, and 
135), as well as 
exposure to 
vitamin K2 
      
Figure 11. Schematic representation (summary) of the impact of transcription factors (like SP1, ETS1, and RUNX1), mi‐
croRNA species possibly constituting a minimal and sufficient “osteoblast”-like signature (miR-149,-328,-27,-29,-133,
and-135), and vitamin K2 (e.g. MK-7) on the stability of the osteoblast and fibroblast/HUVEC/VIC phenotype (i.e. min‐
eralizing facilitating and mineralization prohibiting) development and/or maintenance.
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enhance the transcription of factors (cEBPA, ATF3, Stat3, and PIAS1) known to counteract
chondrocyte development induced by TGFβ-R and Sox9. Enhancing the level of miR-149 (i.e.
the corresponding pre-miR) will favor chondrogenesis at the expense of osteoblast differen‐
tiation. Hence, miR-149 may be defined as a “switch-miR”.
In an excellent review, Goettsch et al, [18] list up-and down-regulated microRNA species in
coronary artery disease, aortic stenosis and arteriosclerosis obliterans, of which several, e.g.
29a, 125b, 135b, and 204, having been shown targeting osteogenic markers (like BMP2, DKK1,
RANKL, Osterix, Runx2, SMADs, and BMP-2), and 335-5p and 155, known to target calcifica‐
tion inhibitors (like MGP and Fetuin-A). However, this is the first time it has been shown that
microRNAs involved in reciprocal regulatory loops with transcription factors are able
to ”determine” whether a cell type will be mineralizing or not.
6.2. Gene expression profiles as markers for osteoblast and fibroblast/HUVEC/VIC analyses
The tables showing the impact of vitamin K2, and vitamin K2, and cytokines, list various
marker gene expression profiles, as well as mineralizing surface obtained with Alizarin red S
in 2D-cell cultures. The parameters are selected from a set of articles featuring the character‐
istics of mineralizing osteoblasts, as well as calcifying soft tissue fibroblast like cells with
emphasis on CSNK1A1, WNT3A, DKK1 (signaling molecules), MSX2, Runx2, Osterix=SP7
(transcription factors), collagen1α1, osteocalcin, matrix GLA protein (matrix structural
proteins), MMP9, OPN=SPP1 (extracellular bioactive molecules=proteinase, hydroxyapatite
binder). PIT-1=POU1F1 (Na+-phosphate transporter), and RANKL (activator of NFκB) and
OPG (osteoclast inhibitory factor), as well as microRNA species contained within various miR-
“signatures” [36, 38] of osteoblasts, where they inhibit factors responsible for osteoblastogen‐
esis and expression of biomolecules necessary for mineralization of the cellular matrix. As
pointed out elsewhere (under results), the pattern of parameter modulation of osteoblasts and
fibroblasts/HUVEC/VIC genes and microRNA expression is compatible with a strengthening
of the osteoblast phenotype when the transcription factors SP1, ETS1, or RUNX1 are reinforced,
or when microRNAs (e.g. mir-149, -328 (as well as -204, -211,- 27b, and -133b; data not shown
in this chapter) are targeted in particular.
6.3. The impact of vitamin K2 on the mineralizing properties of cells
Vitamin K2 (MK-7 (or its metabolite MK-4) was shown to be involved in the regulatory loops
consisting of microRNAs and transcription factors (TFs), as stated above. MK-7/MK-4, by
binding to the transcription factor SXR/PXR/NR1I2 is able to connect to the looping system via
miR-760, JUNB, and miR-597. The microRNA species 597 thus putatively targets (as envisaged
by the Mir@nt@n and TargetScan algorithms): APC2, BMP-1,CD44, CTNNA1, CTNNB1,
CTNNBL1, FOS, FOXA2, FOXA3, FOXO3, FOXP3, FOXP4, GATA6, GATAD2A, HES1, IL-17D,
IRF4, JUNB, MSX1, NFATC4, NOTCH2, RORC, RUNX1, RUNX2, RUNX3, SMAD2, SMAD3,
SMAD4, SMAD7, SOCS2, SOX4, SOX6, SOX9, SOX11, SP1, SP2, SP4, SP6, SP8, SPRY1, SPRY3,
STAT1, TGFB-2, VLDLR, WNT2, and WNT9B.
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These genes are all heavily involved in different signaling pathways determining the devel‐
opment of mineralizing properties, as well as the differentiation of Th-2 and Th-17 cells from
precursor immune cells, i.e. T-regulatory cells [105]. It may therefore be asserted that vitamin
K2 plays an important modulatory role in: 1) the homeostasis of mineral deposits, i.e. calcifi‐
cation of bone and decalcification of soft tissues, as well as 2) the process of soft tissue
infiltration by immune cells, which eventually leads to untoward calcification.
However, when searching various databases for putative interactions between microRNA-
species involved in reciprocal regulatory loops with transcription factors (i.e. miR-149, -328,
-29, -27, -23, -34a, -133, -220c, -597, -522) for putative interference with the transcription/
translation of NFKB1, NFKB2, and/or with their subunits RELA/RELB, known to be important
for the differentiation of inflammatory macrophages and Th-cells, no interactions could be
predicted. Hence, the well-known modulatory effect of vitamin K2 on osteoclasts and Th-cells
related to bone mass and inflammation, respectively, most certainly are not determined
directly by the subject reciprocal regulatory loops, as suggested by the coupling of SXR=NR1I2
to FOS, via the miR-7/JUNB/miR-597 axis.
6.4. The overall modulatory effect of reciprocal regulatory loops involving transcription
factors and microRNAs, and interference from vitamin K2
From the data presented here, it may be hypothesized that certain transcription factors and
microRNA species are heavily involved in determining whether a given cell type will express
mineralizing properties or not. In this context, it would be beneficial to exploit this knowledge
to directly reinforce mineralization of bone (via osteoblasts) and block the calcification of soft
tissues (induced by fibroblasts/HUVECs/VICs in blood vessels and heart valves) due to
senescence or active inflammatory processes involving macrophages and T-cells, through a
gene therapy program.
However, by optimization of tissue exposure to vitamin K2, one may both directly and
indirectly obtain similar results, since vitamin K2 (MK-7 or MK-4 or both) affects the reciprocal
regulatory loops, reinforcing both the osteoblast and fibroblast/HUVEC/VIC phenotypes, both
in the absence and presence of cytokines derived from active, inflammatory Th-cells.
7. Summary and future perspectives
The present text features the dynamic interaction between important biological player
molecules, determining the spectrum of features expressed by different cell types exposed to
the same ambient environmental factors (e.g. oxygen, nutrients and hormones/growth factors).
Osteoblasts and soft tissue cells, like fibroblasts/HUVECs/VICs, respond to the same bioactive
molecules, however, osteoblasts mineralize bone matrix, while the others do not normally
calcify soft tissues. We have shown that regulatory looping systems consisting of microRNAs
and transcription factors (TFs) may determine whether mineralization is going to take place
or not, and that the cell/organ homeostasis is disrupted in the presence of cytokines from
inflammatory cells (Th-cells).
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By manipulating these loops, containing several members of the epigenetic machinery, one
may strengthen wanted cell phenotypes (e.g. osteoblasts in patients with osteoporosis) and
weaken unwanted characteristics (e.g. calcifying fibroblast like cells in the elderly or patients
suffering from hypertension, diabetes, end-stage renal disease, hyperlipidemia and other
diseases). If gene therapy is not warranted or wanted, one may resort to optimal “vitamin K2
therapy”, since MK-7 was shown to normalize and strengthen the mineralizing osteoblast
phenotype, and weaken the mineralizing “fibroblast” phenotype in the presence of inflam‐
matory cytokines.
We have previously shown that the regulatory looping system also contains histone deacety‐
laces (HDACS, including the Sirtuin class, the latter responding to the energy state of an organ)
(see Fig. 4). Sirtuins may respond to small activator molecules [106, 107], such as plant
polyphenols, which confer their activating potential through FOXO3 binding to the Sirt1
mRNA. Sirt1 transcription is activated in mature osteoblasts (where miR-16 levels are dimin‐
ished), compared to other cell types. Hence, the FoxA/FoxO gene activating system, also driven
by vitamin K2, may be further stimulated (synergistically?) by Sirt activators found in natural
foods, thus conserving the osteoblast phenotype better during ageing and or inflammatory
processes. It should not surprise anyone, if soft tissue cells like fibroblasts/HUVECs/VICs will
respond in an opposite manner to the same polyols, reinforcing the anti-calcifying properties
of vitamin K2 on soft tissues like blood vessels and heart valves.
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